Bellevue Group AG
ZURICH, null · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$4.82B2026 Q3
Positions154
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.47.1%
What Changed This Quarter?
Top Holdings
AMGN
Amgen
7.5%
GILD
Gilead Sciences
6.7%
VRTX
Vertex Pharmaceuticals Inc
6.3%
ARGX
Argenx
5.8%
REGN
Regeneron Pharmaceuticals
4.4%
RVMD
Revolution Medicines
4.3%
INSM
Insmed
3.6%
VRDN
Viridian Therapeutics
3.0%
New / Increased
24 new · 41 increased
KODNEW
Kodiak Sciences
0.9%
DMRANEW
Damora Therapeutics
0.8%
ANRONEW
Alto Neuroscience
0.6%
LBRXNEW
LB Pharmaceuticals
0.6%
EPRXNEW
Eupraxia Pharmaceuticals
0.5%
BIIB
Biogen
2.8%
+176800.6%
REGN
Regeneron Pharmaceuticals
4.4%
+77.8%
INCY
Incyte
1.2%
+100809.9%
Reduced / Exited
67 reduced · 18 sold out
VERA
Vera Therapeutics
0.0%
-99.1%
IONS
Ionis Pharmaceuticals
0.0%
-99.9%
SYK
Stryker
1.1%
-31.0%
UNH
UnitedHealth
0.7%
-34.9%
IMCR
Immunocore
1.4%
-18.8%
NUVLEUREXIT
Nuvalent
2.7%
CRNXGBPEXIT
Crinetics Pharmaceuticals In
2.1%
RAREEXIT
Ultragenyx Pharmaceutical In
1.4%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.